Wednesday, September 21, 2016

Hepatitis Australia - Pharmaceutical Benefits Advisory

First pan-genotypic, interferon-free regimens for hepatitis C a step closer
20 September 2016

Hepatitis Australia will be gathering information from people living with hepatitis C who will benefit from the latest medicines to be considered by the Pharmaceutical Benefits Advisory Committee. In particular we would like input from people living with hepatitis C genotypes 2, 3, 4, 5 and 6.

Hepatitis Australia will be making a submission and would welcome your input ahead of the November PBAC meeting.

The medicines being considered at the November meeting of PBAC include:
  • Sofosbuvir (400mg) + velpatasvir (100mg) – Epclusa® by Gilead Sciences
  • Ledipasvir (90mg) + sofosbuvir (400mg) – Harvoni® by Gilead Sciences
  • Paritaprevir (75mg) + ritonavir (50mg) + ombitasvir (12.5mg) – Technivie® by AbbVie
The most significant thing to note regarding these applications is that it heralds the first pan-genotypic, interferon-free regimens for hepatitis C. Epclusa is a new treatment for genotypes 1-6 and Gilead is also seeking to expand the use of Harvoni to other genotypes. Technivie is for the treatment of genotype 4.

Further details
Add your voice for the upcoming PBAC submission in November

1 comment:

  1. You may want to check Dr. James Freeman and the Fixhepc Buyers Club. There's a veritable goldmine of Hep C patients, in various stages of treatment, pretreatment, and post treatment that may be willing to help with gathering the information you seek for the PBA Committee.
    As for those who need a different option than what is offered by the Pharmaceutical companies, there are, SAFE, AFFORDABLE, LEGAL, GENERIC HCV MEDS, SENT TO YOU DIRECTLY. Check out website for free help and support.